Академический Документы
Профессиональный Документы
Культура Документы
com
Multiple Sclerosis:
Principles,& treatment Presented By: Medic Yatra
Email: enquiry@medicyatra.com
1-Overreview
Multiple Sclerosis
Overview
Email: enquiry@medicyatra.com
- Chronic, inflammatory, demyelinating disease its not common - Affects the myelin sheath and axons of the Central Nervous System (CNS) - Progressive clinical or subclinical course - Common cause of disability in young adults
http://www.spermbankcal Youre not alone ifornia.com/buy-sperm Worldwide, 2.5 million people have MS online.h
MS currently affects 400,000 Americans Incidence & prevalence in iran is not clear Every week, 200 new people are diagnosed
in the US
Email: enquiry@medicyatra.com
Email: enquiry@medicyatra.com
2-Ethiology
Email: enquiry@medicyatra.com
Is MS a Hereditary Disease?
Genetic factors
First- and second-degree relatives are at
increased risk
Susceptibility gene
Major histocompatibility
complex (MHC) on chromosome 6
Email: enquiry@medicyatra.com
MS plaques contain
- Complement - Immunoglobulins - (These indicate disruption of BBB and local production of Ig) -TFN(gamma) TNF, IL-2
There is strong evidences that it has immunological base 1-CSF changes (cells;oligoclonal bands) 2-Response to immunomodulators 3-Specific HLA
Email: enquiry@medicyatra.com
MS
Immunological factors
Email: enquiry@medicyatra.com
3-The Biology of MS
Brain
Copyright @
Myelin surrounds the nerve fibers, protecting them like the coating of a wire1
Myelin Cell body
Myelin
Email: enquiry@medicyatra.com
Email: enquiry@medicyatra.com
.
Copyright @ Forever Medic Online Pvt. Ltd
. How is MS monitored?
MRI showing no signs of damage MRI showing an active lesion* MRI showing permanent damage
These images may also help detect silent damage (lesions detected by MRI that do not
result in symptoms)1
The impact of this damage depends on the destructiveness of the lesion and where it
*The exact relationship between MRI findings and the clinical status of patients is unknown.
is located
Email: enquiry@medicyatra.com
4-Pathophysiology
Email: enquiry@medicyatra.com
mechanism
NORMAL CONDUCTION
ABNORMAL CONDUCTION
Email: enquiry@medicyatra.com
Main Component
Inflammation and demyelination Atrophy, axonal loss, and increasing tissue destruction (less Gd-defined inflammation, demyelination ongoing)
1-All the symptoms are upper motor 2-Dissamination in time & space 2-Conduction block is cause of fatigue 3-Agrravation with heat 4-remyelination is not perfect 5-plaques could be in silent areas
Immunological pathological physiologic clinical
Email: enquiry@medicyatra.com
Treatment Goals
Reduce (control) relapses Delay disease progression Delay disability Alleviate symptoms
Email: enquiry@medicyatra.com
Early Treatment
The National MS Society recommends: Initiation of therapy with an immunomodulator is advised as soon as possible following a definite diagnosis of MS with a relapsing course, and may be considered for selected patients with a first attack who are at high risk for MS.
Source: Recommendation of the Executive Committee of the Medical Advisory Board of the Natl MS Society www.nationalmssociety.org/Sourcebook-Early.asp. Accessed May 17, 2006.
Email: enquiry@medicyatra.com
Current Therapies:
Immunosuppressant's and Immunomodulators
Corticosteroids Interferons :
Betaseron (interferon -1b) Avonex (interferon -1a) Rebif (interferon -1a)
Email: enquiry@medicyatra.com
Corticosteroids
Symptomatic management Used in moderate-to-severe exacerbations IV methylprednisolone 500 mg/day for five days followed by oral prednisone (optional) Hasten clinical recovery Delay recurrence of neurologic events Does not alter the course of MS
Copyright @ Forever Medic Online Pvt. Ltd
Email: enquiry@medicyatra.com
Email: enquiry@medicyatra.com
Interferons :
Avonex-lyo-vial
May delay progression of disability This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Copyright @ Forever Medic Online Pvt. Ltd
Email: enquiry@medicyatra.com
Interferons :
Rebif
Interferon -1a Indication: relapsing/remitting forms of MS Dose: 22 or 44 mcg SC 3 times per week Decreases frequency of relapse Delays the increase in the volume of lesions
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Interferons :
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Flu-like symptoms Chills Fever Muscle aches Asthenia (weakness) Betaseron and Rebif have injection site reactions
Severe depression Suicide Seizures Cardiac effects Anemia Elevated liver enzymes
Severe hepatic
injury, including cases of hepatic failure, has been This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark. reported in patients Copyright @ Forever Medic Online taking Avonex
Pvt. Ltd
Email: enquiry@medicyatra.com
Noninterferons:
Copaxone (glatiramer acetate) PFS
Indication: Reduction of frequency of relapses in patients with RRMS Dose: 20 mcg SC once daily Reduces the frequency of exacerbations Moderately reduces the development of new lesions
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Auto Injectors
All provided free from manufacturer. Rebiject and Copaxone need a prescription. This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Antineoplastics:Nonantrone
Indication: Reduction of relapse rate and clinical disability in patients with SPMS, PRMS or worsening RRMS Dose: 12 mg/m2 as short IV infusion (five minutes to 15 minutes every three months)
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Antineoplastics:
Novantrone (cont.)
Reduces exacerbation rate Prolongs time to first treated relapse Improves EDSS scores versus baseline
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Novantrone
Mechanism of Action
Inhibits or prevents the development of any uncontrolled new or abnormal growth, such as a neoplasm or tumor Suppresses B-cell and T-cell immunity
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Novantrone
Side Effects
Moderate to severe
Bone marrow suppression
Neutropenia (decreased WBC and ANC) Thrombocytopenia (decreased platelets) Acute myelogenous leukemia
Cardiac toxicity
Congestive heart failure (CHF) Decreased left ventricular ejection fraction (LVEF) Maximum cumulative dose 140 mg/m2
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Novantrone
Side Effects
Moderate to severe
Teratogenic effects
Fetal growth retardation in rats Shortened gestation period Excreted in breast milk
Mild to moderate
Increased liver enzymes Nausea Alopecia (hair loss - transient)
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Novantrone
Contraindications
LVEF < 50% CHF Baseline neutrophil count < 1500 cells/mm3 Pre-existing myelosuppression Abnormal LFT Pregnancy, breastfeeding Cumulative lifetime dose 140 mg/m2
This page contains prescription brand drugs that are registered or registered trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Immunosuppressant's
Show only slight evidence of benefit in MS Used only for progressive MS Associated with serious side effects
Thiopurines (Imuran) Methotrexate Alkylating agents (Cytoxan) Cyclosporine
This page contains prescription brand drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with Caremark.
Email: enquiry@medicyatra.com
Symptomatic Treatments
Problem
Spasticity
Symptoms
Management
Painful spasms in the lower Remove irritating factors and upper limbs Physical therapy, baclofen, diazepam, dantrolene Trigeminal neuralgia, pain, tonic seizures Feeling tired (morning or early afternoon) Common, occurs in high percentage of patients carbamazepine, Neurontin, phenytoin Energy conservation, amantidine Anti-depressants
Inability to produce/ sustain Behavioral therapy an erection Viagra, Muse Urgency, frequency and retention Detrol, Ditropan, Botox
Email: enquiry@medicyatra.com
Conclusion
Early treatment may delay disability and enhance recovery from relapses Treatment must be a cooperative effort between multidisciplinary team of healthcare providers Medications are not a cure for MS
Email: enquiry@medicyatra.com
Challenges
Challenges for the person with MS
Physical difficulties Financial concerns Social issues Emotional issues
Email: enquiry@medicyatra.com
Email: enquiry@medicyatra.com
5-Summary
Conclusion
1-Multiple sclerosis is not a common Disease 2-Its the result of Different mechanisms 3-the most probable mechanism is immunological